Your search for supplemental oxygen returned 52 results

Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.

The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.

The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.

Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.

Currently, there are no approved treatments for COVID-19, however, several investigational therapies are in the works.

The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.

The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.

The studies evaluated routine clinical practice data from more than 800 hospitals in the US.

Both randomized, placebo-controlled trials are expected to enroll approximately 1000 hospitalized patients.

Findings showed that the trial did not meet statistical significance on the primary endpoint.